PL2481429T3 - Sekwencja cięcia specyficzna dla mmp-14 - Google Patents

Sekwencja cięcia specyficzna dla mmp-14

Info

Publication number
PL2481429T3
PL2481429T3 PL12160565T PL12160565T PL2481429T3 PL 2481429 T3 PL2481429 T3 PL 2481429T3 PL 12160565 T PL12160565 T PL 12160565T PL 12160565 T PL12160565 T PL 12160565T PL 2481429 T3 PL2481429 T3 PL 2481429T3
Authority
PL
Poland
Prior art keywords
mmp
specific cutting
cutting sequence
sequence
specific
Prior art date
Application number
PL12160565T
Other languages
English (en)
Inventor
Jason Gill
Paul Loadman
Robert Falconer
Laurence Patterson
Jennifer Atkinson
Michael Bibby
Original Assignee
Incanthera Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incanthera Limited filed Critical Incanthera Limited
Publication of PL2481429T3 publication Critical patent/PL2481429T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL12160565T 2007-04-12 2008-03-27 Sekwencja cięcia specyficzna dla mmp-14 PL2481429T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0707034.5A GB0707034D0 (en) 2007-04-12 2007-04-12 Compounds
EP12160565.3A EP2481429B1 (en) 2007-04-12 2008-03-27 MMP-14 specific cleavage sequence
EP08718877.7A EP2134372B1 (en) 2007-04-12 2008-03-27 Mmp activated vascular disrupting agents

Publications (1)

Publication Number Publication Date
PL2481429T3 true PL2481429T3 (pl) 2018-10-31

Family

ID=38116587

Family Applications (3)

Application Number Title Priority Date Filing Date
PL08718877.7T PL2134372T3 (pl) 2007-04-12 2008-03-27 Środki niszczące naczynia aktywowane przez mmp
PL12160565T PL2481429T3 (pl) 2007-04-12 2008-03-27 Sekwencja cięcia specyficzna dla mmp-14
PL12160556.2T PL2481428T3 (pl) 2007-04-12 2008-03-27 Środki niszczące naczynia aktywowane przez mmp

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08718877.7T PL2134372T3 (pl) 2007-04-12 2008-03-27 Środki niszczące naczynia aktywowane przez mmp

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12160556.2T PL2481428T3 (pl) 2007-04-12 2008-03-27 Środki niszczące naczynia aktywowane przez mmp

Country Status (16)

Country Link
US (4) US8691751B2 (pl)
EP (4) EP2481428B1 (pl)
JP (4) JP5537413B2 (pl)
CY (1) CY1120368T1 (pl)
DK (3) DK2481429T3 (pl)
ES (3) ES2573682T3 (pl)
GB (1) GB0707034D0 (pl)
HK (1) HK1258466A1 (pl)
HR (1) HRP20181043T1 (pl)
HU (3) HUE027528T2 (pl)
LT (1) LT2481429T (pl)
PL (3) PL2134372T3 (pl)
PT (1) PT2481429T (pl)
SI (1) SI2481429T1 (pl)
TR (1) TR201807811T4 (pl)
WO (1) WO2008125800A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0707034D0 (en) * 2007-04-12 2007-05-23 St Andrews The Compounds
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
GB2516882A (en) * 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
US9169337B2 (en) 2014-03-12 2015-10-27 Chevron Phillips Chemical Company Lp Polymers with improved ESCR for blow molding applications
KR102754019B1 (ko) * 2014-10-29 2025-01-14 바이시클러드 리미티드 Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
GB2545169B (en) * 2015-12-01 2019-10-09 Ellipses Pharma Ltd Taxane Prodrug Comprising A Membrane Type Matrix Metalloproteinase Cleavage Site
CN111065381A (zh) 2017-07-07 2020-04-24 鲁汶天主教大学 无血管或者少血管的微肿瘤的治疗

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030009388A (ko) 2000-03-15 2003-01-29 브리스톨-마이어스 스퀴브 파마 컴파니 펩티다제-절단성인 표적화 항종양 약물 및 그의 치료상 용도
GB0018240D0 (en) * 2000-07-25 2000-09-13 Pharmacia & Upjohn Spa Polymeric conjugates of antitumor agents
GB0105929D0 (en) * 2001-03-09 2001-04-25 Btg Int Ltd Physiologically activated prodrugs
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
CN101146826A (zh) 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
US20090022782A1 (en) 2005-02-25 2009-01-22 National University Corp. Hokkaido University Blood Retainable Device Exhibiting Selective Degradability in Tumor Tissue
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
GB0707034D0 (en) 2007-04-12 2007-05-23 St Andrews The Compounds
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
GB2516882A (en) 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic

Also Published As

Publication number Publication date
EP2481429A3 (en) 2013-07-03
US9956296B2 (en) 2018-05-01
HUE029080T2 (en) 2017-01-30
HUE038633T2 (hu) 2018-11-28
HUE027528T2 (en) 2016-10-28
JP5911908B2 (ja) 2016-04-27
ES2573682T3 (es) 2016-06-09
HK1258466A1 (en) 2019-11-15
US20160243252A1 (en) 2016-08-25
EP2481429A2 (en) 2012-08-01
TR201807811T4 (tr) 2018-06-21
US20180228910A1 (en) 2018-08-16
JP5931952B2 (ja) 2016-06-08
ES2683168T3 (es) 2018-09-25
US20100168036A1 (en) 2010-07-01
JP5537413B2 (ja) 2014-07-02
SI2481429T1 (en) 2018-08-31
GB0707034D0 (en) 2007-05-23
JP2010523632A (ja) 2010-07-15
HK1174534A1 (en) 2013-06-14
PT2481429T (pt) 2018-06-19
DK2134372T3 (en) 2016-06-06
EP2481429B1 (en) 2018-05-09
DK2481428T3 (en) 2016-06-13
US9358303B2 (en) 2016-06-07
CY1120368T1 (el) 2019-07-10
JP6170590B2 (ja) 2017-07-26
JP2014193871A (ja) 2014-10-09
ES2573228T3 (es) 2016-06-06
US20140179592A1 (en) 2014-06-26
EP2481428A2 (en) 2012-08-01
PL2134372T3 (pl) 2016-09-30
EP2134372B1 (en) 2016-02-24
US8691751B2 (en) 2014-04-08
EP2134372A2 (en) 2009-12-23
PL2481428T3 (pl) 2016-09-30
WO2008125800A2 (en) 2008-10-23
US10556014B2 (en) 2020-02-11
JP2014196304A (ja) 2014-10-16
WO2008125800A3 (en) 2008-12-04
DK2481429T3 (en) 2018-07-30
EP3348282A1 (en) 2018-07-18
EP2481428A3 (en) 2013-07-24
HRP20181043T1 (hr) 2018-09-21
EP2481428B1 (en) 2016-03-02
JP2016190848A (ja) 2016-11-10
LT2481429T (lt) 2018-09-10

Similar Documents

Publication Publication Date Title
CY2017016I1 (el) Αναστολεις πρωτεασωματος
DE602007010545D1 (de) Schneidegerät
DK2164893T3 (da) Polyethylenskum
PL2857132T3 (pl) Dwustronna wkładka skrawająca
BRPI0813500A2 (pt) Compostos antivirais
HUE056966T2 (hu) Horonymarási eljárás
BRPI0821086A2 (pt) Compostos inseticidas
BRPI0912944A2 (pt) cortador de chanfradura
BRPI0811264A2 (pt) Compostos
BRPI0809996A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila
EP2162436A4 (en) NEW CASE OF RENININHIBITORS
BRPI0815181A2 (pt) Compostos
DE602007005796D1 (de) Schneidegerät
IT1391879B1 (it) Segatrice
DE102009031940B8 (de) Sägeeinrichtung
HUE038633T2 (hu) MMP-14 specifikus hasítási szekvencia
PL2357183T3 (pl) Związki morfinanu
BRPI0814613A2 (pt) Compostos
FI20070540A0 (fi) Teräsovitelma
DK2334586T3 (da) Anhugningsbøjle
FI20085370L (fi) Pituusleikkuri
FI8012U1 (fi) Radan katkaisulaite
FI7877U1 (fi) Kaksiteräinen komponenttisaha
ITBO20080005U1 (it) Insieme di fresa